Broker updates starting to flow in... CSL - CSL LIMITEDUBS rates...

Broker updates starting to flow in...

CSL - CSL LIMITED
UBS rates CSL as Buy - The broker says the result was solid, with plasma growth particularly strong for the industry as a whole, as well as for the stock outlook.

While swine flu vaccine was expected to lift FY10 profits, the company is set to spend it on research and development, UBS says.

If plasma performance is sustained over the next six months, the analysts expect the business to gradually re-rate to previous levels.

Target falls $1.67 to $42.18.

Target price is $42.18 Current Price is $33.56 Difference:$8.62 - (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately 26% (excluding dividends, fees and charges - negative figures indicate an expected loss).

The company's fiscal year ends in June. UBS forecasts a full year FY10 dividend of 73.00 cents and EPS of 203.00 cents . At the last closing share price the estimated dividend yield is 2.18%. At the last closing share price the stock's estimated Price to Earnings Ratio (PER) is 16.53.

Market Sentiment: 0.9